Moroctocog alfa
| Clinical data | |
|---|---|
| Trade names | ReFacto |
| AHFS/Drugs.com | UK Drug Information |
| ATC code | B02BD02 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider | none |
| Chemical and physical data | |
| Molar mass | 170 kg/mol |
Moroctocog alfa (trade name ReFacto) is a recombinant antihemophilic factor genetically engineered from Chinese hamster ovary (CHO) cell line. Chemically it is a glycoprotein.[1] It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII).[2] It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it is not a von Willebrand factor.
References
- ↑ http://www.abopharmaceuticals.com/ProductSheets/Refacto.pdf
- ↑ (PDF) https://web.archive.org/web/20100531074853/http://www.ema.europa.eu/humandocs/PDFs/EPAR/Refacto/058999en6.pdf. Archived from the original (PDF) on May 31, 2010. Retrieved March 8, 2010. Missing or empty
|title=(help)